<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883766</url>
  </required_header>
  <id_info>
    <org_study_id>DEX002</org_study_id>
    <nct_id>NCT00883766</nct_id>
  </id_info>
  <brief_title>Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1</brief_title>
  <official_title>PCOS and IVF: A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Universitari Dexeus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Universitari Dexeus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare two different IVF-stimulation protocols in patients&#xD;
      affected by PCOS: the use of a Gonadotropin-releasing hormone (GnRH) - antagonist starting on&#xD;
      day 1 of controlled ovarian hyperstimulation (COH) versus a standard long agonist protocol;&#xD;
      in order to assess whether it affects the number and quality of Metaphase II (MII) oocytes&#xD;
      while reducing the risk of hyperstimulation. Since PCOS patients are also likely to be&#xD;
      insulin resistant we also aim to evaluate how metformin affects tha IVF stimulation outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hejinen et al (1) recently conducted a meta-analysis to compare outcomes of conventional IVF&#xD;
      in women presenting with polycystic ovary syndrome (PCOS) and non-PCOS patients. They&#xD;
      compared nine RCTs reporting data on 458 PCOS patients (793 cycles) and 694 matched controls&#xD;
      (1116 cycles) and concluded that in PCOS there is an increased cancellation rate, but more&#xD;
      oocytes retrieved per pick-up and a lower fertilization rate. Overall, PCOS and control&#xD;
      patients achieved similar pregnancy and live birth rates per cycle. The incidence of ovarian&#xD;
      hyperstimulation syndrome (OHSS) after oocyte retrieval was rarely reported.&#xD;
&#xD;
      Our results are in accordance with this meta-analysis. Therefore, if the pregnancy and&#xD;
      abortion rates in PCOS and controls do not differ, the main problem when dealing with PCOS in&#xD;
      IVF is OHSS. This condition can be approached by using an antagonist instead of an agonist,&#xD;
      by changing the kind of ovulation trigger and by co-treating patients with metformin.&#xD;
&#xD;
        -  One of the currently debatable issues regarding the use of GnRH antagonists refers to&#xD;
           the timing of GnRH antagonist initiation. A fixed protocol starting antagonist&#xD;
           arbitrarily on Day 6 of stimulation has been used in all introductory comparative trials&#xD;
           employing a daily antagonist administration (2). Following these trials, a flexible&#xD;
           antagonist initiation by a follicle of 14-15 mm has been evaluated. Currently,&#xD;
           initiation of antagonist in the early follicular phase in PCOS patients has been&#xD;
           performed by Lainas and coll. (3) who treated patients with PCOS either with a long GnRH&#xD;
           agonist scheme or a fixed day-1 GnRH antagonist protocol and concluded that initiation&#xD;
           of GnRH antagonist concomitantly with recombinant FSH on day 1 is associated with an&#xD;
           earlier follicular growth and a different hormonal environment during the follicular&#xD;
           phase when compared with the long agonist protocol. This may lead to a reduction in the&#xD;
           incidence of OHSS.&#xD;
&#xD;
        -  Over the past 15 years, it has become increasingly recognized that insulin resistance is&#xD;
           central to the pathogenesis of the PCOS (4). Metformin, a biguanide insulin-lowering&#xD;
           agent, has been extensively investigated in the management of PCOS. Two recent&#xD;
           systematic reviews (5, 6) demonstrated that metformin improves reproductive function of&#xD;
           some women with PCOS. Metformin also appeared to improve the outcomes of ovulation&#xD;
           induction therapies when combined with clomiphene and gonadotrophin. Tang et al.&#xD;
           recently studied PCOS overweight patients undergoing IVF to whom they administered 850&#xD;
           mg bid or placebo 28 days prior to the stimulation (7). They concluded that short-term&#xD;
           co-treatment with metformin for patients with PCOS undergoing IVF/ICSI cycles does not&#xD;
           improve the response to stimulation but significantly improves the pregnancy outcome and&#xD;
           reduces the risk of OHSS.&#xD;
&#xD;
      The aim of this study is to verify if using an antagonist the number and quality of MII&#xD;
      oocytes is equal compared to a standard long agonist protocol while reducing the risk of&#xD;
      hyperstimulation.&#xD;
&#xD;
      Outcome measures:&#xD;
&#xD;
      Primary endpoints:&#xD;
&#xD;
        -  Oocytes MII Secondary endpoints&#xD;
&#xD;
        -  Fertilization rates&#xD;
&#xD;
        -  Pregnancy rates&#xD;
&#xD;
        -  Miscarriage rates&#xD;
&#xD;
        -  Incidence of OHSS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Oocytes MII retrieved per patient</measure>
    <time_frame>1 Day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization rates</measure>
    <time_frame>24 hours after pick-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rates</measure>
    <time_frame>4 weeks after pick-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of OHSS</measure>
    <time_frame>From ovulation triggering to two weeks after pick-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>In Vitro Fertilization</condition>
  <arm_group>
    <arm_group_label>Long agonist protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Antagonist protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Controlled ovarian hyperstimulation for IVF with a long agonist protocol</intervention_name>
    <description>Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI&gt;30, HOMA &gt;3.8, G/I ratio &lt;4.5&#xD;
Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days&#xD;
Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst &gt;10 mm&#xD;
Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)&#xD;
Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound&#xD;
Day before HCG: stop rFSH&#xD;
Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)&#xD;
Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C&#xD;
Day 7 after pick-up: ultrasound, patient evaluation.&#xD;
Day 14 after pick-up: HCG in blood&#xD;
Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive&#xD;
(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)</description>
    <arm_group_label>Long agonist protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Controlled ovarian hyperstimulation for IVF with an antagonist protocol</intervention_name>
    <description>Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI&gt;30, HOMA &gt;3.8, G/I ratio &lt;4.5&#xD;
Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst &gt;10 mm&#xD;
Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)&#xD;
Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO&#xD;
Day before HCG: stop rFSH + cetrorelix&#xD;
Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)&#xD;
Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C&#xD;
Day 7 after pick-up: ultrasound, patient evaluation.&#xD;
Day 14 after pick-up: HCG in blood&#xD;
Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)</description>
    <arm_group_label>Antagonist protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PCOS patients according to the Rotterdam consensus criteria&#xD;
&#xD;
          -  Presence of both ovaries&#xD;
&#xD;
          -  Absence of endometriomas detected at ultrasound&#xD;
&#xD;
          -  FSH &lt; 10 IU/L on day 3 of the cycle&#xD;
&#xD;
          -  E2 &lt; 80 pg/mL, and Pg &lt; 1.6 ng/mL at initiation of stimulation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congenital adrenal hyperplasia&#xD;
&#xD;
          -  Cushing's syndrome&#xD;
&#xD;
          -  Androgen-producing tumours&#xD;
&#xD;
          -  Hyperprolactinaemia and thyroid dysfunction&#xD;
&#xD;
          -  Age &gt; 38 years&#xD;
&#xD;
          -  Serum FSH levels &gt; 10 mIU/ml&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fulvia Mancini, M.D. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetric, Gynecology and Reproductive Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Universitari Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.dexeus.com</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update. 2006 Jan-Feb;12(1):13-21. Epub 2005 Aug 25.</citation>
    <PMID>16123051</PMID>
  </reference>
  <reference>
    <citation>Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod. 2002 Apr;17(4):874-85.</citation>
    <PMID>11925376</PMID>
  </reference>
  <reference>
    <citation>Lainas TG, Petsas GK, Zorzovilis IZ, Iliadis GS, Lainas GT, Cazlaris HE, Kolibianakis EM. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development. Hum Reprod. 2007 Jun;22(6):1540-6. Epub 2007 Mar 8.</citation>
    <PMID>17347165</PMID>
  </reference>
  <reference>
    <citation>Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004 Jan;60(1):1-17. Review.</citation>
    <PMID>14678281</PMID>
  </reference>
  <reference>
    <citation>Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril. 2003 Jan;79(1):1-13. Review.</citation>
    <PMID>12524053</PMID>
  </reference>
  <reference>
    <citation>Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update. 2007 Nov-Dec;13(6):527-37. Epub 2007 Sep 1. Review.</citation>
    <PMID>17767003</PMID>
  </reference>
  <reference>
    <citation>Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006 Jun;21(6):1416-25. Epub 2006 Feb 24.</citation>
    <PMID>16501038</PMID>
  </reference>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>April 17, 2009</study_first_submitted>
  <study_first_submitted_qc>April 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2009</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <name_title>Fulvia Mancini</name_title>
    <organization>Departamento de Obstetricia, Ginecologia y Reproducción</organization>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>GnRH Antagonist</keyword>
  <keyword>Long Agonist Protocol</keyword>
  <keyword>OHSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

